Last reviewed · How we verify
NCT07046312
Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level
trial in Psoriatic Arthritis (PsA) in 60 participants. Not yet recruiting.
1 April 2027
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 July 2025 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across Egypt |
Conditions studied
- Psoriatic Arthritis (PsA) — all drugs for Psoriatic Arthritis (PsA) →
- Subclinical Right Ventricular Systolic Dysfunction — all drugs for Subclinical Right Ventricular Systolic Dysfunction →
Sponsor
Ain Shams University
Who can join
Adults 20 to 50, any sex, with Psoriatic Arthritis (PsA) or Subclinical Right Ventricular Systolic Dysfunction. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Detecting subclinical right ventricular systolic dysfunction in PsA patients
Time frame: Up to 24 months
Detecting subclinical right ventricular systolic dysfunction in PsA using 2D strain transthoracic echo and its relation to serum endostatin level
Sponsor's own description
The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07046312
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriatic Arthritis (PsA)
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07486843 — Preventing Structural Damage in Early Psoriatic Arthritis · Phase 4 · recruiting
- NCT07160231 — REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases · Phase 4 · recruiting
- NCT06628206 — Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis · Phase 1 · recruiting
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07046312 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07046312.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing